JERUSALEM, July 1 (Reuters) - Teva Pharmaceutical

Industries said on Monday it believes its patents were

properly listed, following a report in the Washington Post that

U.S. regulators had opened a patent investigation into the

Israel-based company.

"Teva believes that its patents are properly listed in the

Orange Book and continues to stand behind the company's

intellectual property," it said in a statement to Reuters.